Bio-Process Systems Alliance Elects New Directors from Sanofi Pasteur, Catalent and Dow Corning
The Bio-Process Systems Alliance (BPSA) elected three new members to its Board of Directors at a December 5, 2012, meeting in Washington, D.C.
Joining the BPSA Board for 2013-2015 terms are:
Kirsten A. Strahlendorf – Senior Scientist in the Bioprocess Research and Development/Formulation and Stability Platform at Sanofi Pasteur , Toronto, Canada, where she has worked for more than seven years. Sanofi Pasteur is the vaccines division of Sanofi Aventis, one of the largest pharmaceutical companies in the world.
Bill Hartzel – Product Manager at Catalent Pharma Solutions , a global leader in development solutions and advanced drug delivery technologies. He is responsible for the implementation of strategic initiatives for a full suite of biologic and complex pharmaceutical liquid offerings.
Steve Wilkowski – Global Market Leader of Pharmaceutical Processing at Dow Corning Corporation , a global leader in silicones, silicon-based technology and innovation. Wilkowski develops global strategies and leads multifunctional teams in strategy implementation to develop and deliver new business opportunities and product innovations for Medical and Life Science applications.
“We are very pleased about this infusion of talent and expertise into our board proceedings,” said Jerold Martin, Senior Vice President at Pall Life Sciences and Chairman of the Board of BPSA. “Each of these individuals brings a diversity of business and technical knowledge to our leadership team, and each represents a unique aspect of the full single-use value chain, from components to manufacture of sterile drugs and vaccines.”
“Catalent, Sanofi-Pasteur and Dow Corning are representative of the diversity of the user and supply chain in single-use, and having these three individuals on our board is a testament to the growth and diversity of not just BPSA, but also the expansion and interest in the single-use commercial market as a whole,” said Kevin Ott, BPSA’s Washington, D.C.-based Executive Director.
During the December 5 meeting, BPSA leaders discussed plans and roll-out of new Good Manufacturing Practice (GMP) technical guides to be delivered in 2013 and planned for its 3 rd Annual Single-Use Summit, July 15-17, 2013, in Washington, D.C.
The Bio-Process Systems Alliance (BPSA) was formed in 2005 as a trade association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, sharing of best practices, development of consensus guides and business-to-business networking opportunities among its member company employees. BPSA is host of the annual International Single-Use Summit in Washington, D.C.
For more information, please visit www.bpsalliance.org , or contact Executive Director Kevin Ott at email@example.com. BPSA is affiliated with the Society of Chemical Manufacturers and Affiliates (SOCMA).
SOCMA manages a group of separately funded, affiliated associations and consortia, which address specific chemical or process advocacy, regulatory, testing, stewardship and technical issues of common concern or interest to a particular sector of the chemical industry. Learn more at www.socma.com/chemsortia.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com .
more products. better treatments. reliably supplied.™